7.255
前日終値:
$7.495
開ける:
$7.48
24時間の取引高:
1.31M
Relative Volume:
0.51
時価総額:
$807.19M
収益:
$24.30M
当期純損益:
$-145.57M
株価収益率:
-5.4549
EPS:
-1.33
ネットキャッシュフロー:
$-149.17M
1週間 パフォーマンス:
-20.77%
1か月 パフォーマンス:
-15.01%
6か月 パフォーマンス:
+396.58%
1年 パフォーマンス:
+22.26%
Tango Therapeutics Inc Stock (TNGX) Company Profile
TNGX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
TNGX
Tango Therapeutics Inc
|
7.255 | 1.00B | 24.30M | -145.57M | -149.17M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.08 | 108.04B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
476.80 | 60.75B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
582.75 | 61.26B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
825.21 | 50.32B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
316.55 | 34.14B | 4.56B | -176.77M | 225.30M | -1.7177 |
Tango Therapeutics Inc Stock (TNGX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-08-19 | 開始されました | Piper Sandler | Overweight |
| 2024-07-17 | 開始されました | Jefferies | Buy |
| 2024-04-04 | 開始されました | Cantor Fitzgerald | Overweight |
| 2024-02-12 | 開始されました | Piper Sandler | Overweight |
| 2023-12-08 | 開始されました | B. Riley Securities | Buy |
| 2022-10-20 | アップグレード | H.C. Wainwright | Neutral → Buy |
| 2021-09-20 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Tango Therapeutics Inc (TNGX) 最新ニュース
Tango Therapeutics stock gains as Cantor Fitzgerald reiterates Overweight rating - Investing.com
How to build a dashboard for Tango Therapeutics Inc. stockJuly 2025 Selloffs & Low Drawdown Investment Strategies - newser.com
Is Tango Therapeutics Inc. stock entering bullish territoryChart Signals & High Conviction Buy Zone Picks - newser.com
Tango Therapeutics Inc. stock trend outlook and recovery pathWeekly Profit Analysis & Trade Opportunity Analysis Reports - newser.com
Ranking Tango Therapeutics Inc. among high performing stocks via toolsJuly 2025 News Drivers & Entry and Exit Point Strategies - newser.com
Why Tango Therapeutics Inc. stock is trending among retail tradersMarket Sentiment Summary & Technical Entry and Exit Tips - newser.com
Using AI based signals to follow Tango Therapeutics Inc.2025 Market Outlook & Proven Capital Preservation Tips - newser.com
Multi asset correlation models including Tango Therapeutics Inc.2025 Investor Takeaways & Reliable Volume Spike Alerts - newser.com
Tango Therapeutics Inc. (TNGX) Stock Price | Live Quotes & Charts | NSD - StocksToTrade
Guggenheim Maintains Tango Therapeutics (TNGX) Buy Recommendation - Nasdaq
Guggenheim Maintains Buy Rating and Raises Price Target for TNGX - GuruFocus
What analysts say about Tango Therapeutics Inc stockHigh Yield Income Stocks & Low Risk Trading Plans - earlytimes.in
Guggenheim raises Tango Therapeutics stock price target on promising cancer drug data - Investing.com
Tango Therapeutics price target raised to $12 from $10 at Guggenheim - TipRanks
Tango Therapeutics announces $225 million financing - The Pharma Letter
Form 424B5 Tango Therapeutics, Inc. - StreetInsider
Tango Therapeutics prices $210 million stock offering By Investing.com - Investing.com Nigeria
Tango Therapeutics Inc (TNGX) 財務データ
収益
当期純利益
現金流量
EPS
Tango Therapeutics Inc (TNGX) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Third Rock Ventures IV, L.P. | 10% Owner |
Sep 25 '25 |
Sale |
8.02 |
500,000 |
4,008,500 |
13,863,975 |
大文字化:
|
ボリューム (24 時間):